<\/p>\n
Macralfate Suspension<\/strong> tartalmaz sucralfate 1 g per 10 mL<\/strong> in a 200 mL bottle, from a WHO-GMP certified manufacturer. Sucralfate is a mucosal protectant<\/strong>, not an acid-suppressing drug — it is an aluminium-sucrose-octasulfate complex that polymerises into a viscous, adherent paste in the acid environment of the stomach and binds selectively to the surface of ulcers and erosions, forming a physical protective barrier for 6–8 hours. Standard feln\u0151tt adag:<\/strong> 10 mL (1 g) four times daily on an empty stomach — one hour before meals and at bedtime — for 4–8 weeks. Useful for peptic ulcer healing, bile reflux gastritis, NSAID ulcer prophylaxis, radiation-induced oesophagitis, and chemotherapy oral mucositis (off-label). Critical timing rule:<\/strong> sucralfate binds many other medicines and reduces their absorption — separate sucralfate from all other oral medicines by at least 2 hours<\/strong>. Avoid in dialysis patients (aluminium accumulation).<\/p>\n<\/div>\n \ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n Generikus gy\u00f3gyszereink WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3kt\u00f3l sz\u00e1rmaznak, \u00e9s diszkr\u00e9t, egyszer\u0171 csomagol\u00e1sban sz\u00e1ll\u00edtjuk \u0151ket vil\u00e1gszerte \u2014 a csomagon nem szerepel a gy\u00f3gyszer neve. A k\u00e1rty\u00e1s fizet\u00e9sek egy szab\u00e1lyozott feldolgoz\u00f3n kereszt\u00fcl t\u00f6rt\u00e9nnek (a sz\u00e1mlale\u00edr\u00e1sok egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t tartalmaznak \u2014 soha nem \u201cMedsBase\u201d vagy b\u00e1rmilyen gy\u00f3gyszer neve). Kriptovalut\u00e1t \u00e9s SEPA banki \u00e1tutal\u00e1st is elfogadunk. Minden rendel\u00e9st a Reshipment Assurance Policy biztos\u00edt\u00e9k fedez.<\/p>\n Macralfate Suspension is an oral suspension of sucralfate<\/strong> — the basic aluminium salt of sucrose octasulfate. Each 10 mL contains 1 g of sucralfate; the 200 mL bottle therefore provides 20 doses. Sucralfate is an unusual drug because it is not absorbed<\/strong> in any clinically meaningful amount — it works entirely topically in the gut lumen.<\/p>\n In the acid environment of the stomach (pH < 4), sucralfate undergoes protonation and polymerisation<\/strong> into a viscous, sticky, negatively-charged paste. Ulcers and erosions expose positively-charged proteins (especially albumin and fibrinogen) on their surface that the negatively-charged sucralfate polymer binds to selectively. The result is a physical adherent protective coating over the ulcer surface that lasts 6–8 hours and resists acid, pepsin and bile-salt erosion. Sucralfate also stimulates local prostaglandin and bicarbonate secretion at the mucosal surface, increases epidermal-growth-factor binding, and reduces pepsin activity. It does not reduce gastric acid secretion<\/strong> — if you also need acid suppression (most peptic ulcer patients do), a PPI or H2<\/sub> antagonist is added.<\/p>\n Because sucralfate needs an acid environment to polymerise, do not take it together with a PPI or H2<\/sub> antagonist — separate the two by at least 30–60 minutes (sucralfate first, then the acid-suppressant after the meal works well).<\/p>\n Sucralfate heals duodenal ulcers in 4 weeks and gastric ulcers in 8 weeks at 1 g four times daily. Healing rates are comparable to H2<\/sub> antagonists; PPIs are more effective and faster but sucralfate is useful where PPI is contraindicated or where the patient prefers a non-systemic option.<\/p>\n Where stomach acid is not the problem (post-gastrectomy, post-cholecystectomy bile reflux), PPIs offer little benefit. Sucralfate’s mechanical mucosal coating helps in this setting and is one of the few acid-related therapies with a defined niche here.<\/p>\n For lower-risk patients on chronic NSAID therapy, sucralfate can reduce gastritis and ulcer development. PPIs are more effective and are first-line in higher-risk patients.<\/p>\n Sucralfate suspension reduces pain and accelerates healing in radiation-induced oesophagitis (head-and-neck cancer treatment) and radiation proctitis (pelvic radiation). The suspension can be swallowed as an oesophageal coating, or used as a retention enema for proctitis.<\/p>\n Sucralfate suspension used as an oral rinse-and-spit, or rinse-and-swallow, reduces pain and ulcer severity during chemotherapy mucositis. Evidence is limited but supportive.<\/p>\n Some ICU practice has shifted back toward sucralfate or H2<\/sub> antagonists for stress-ulcer prophylaxis in selected ventilated patients, because PPIs increase ventilator-associated pneumonia and C. difficile<\/em> rates. Specialist intensive-care decision.<\/p>\n In refractory reflux despite optimised PPI therapy, adding sucralfate suspension can give symptom benefit by physically coating the eroded distal oesophagus. Take immediately before bedtime as a coating dose.<\/p>\nMi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n
What Macralfate Is<\/h2>\n
How Macralfate Works (Mechanism)<\/h2>\n
Indications — What Macralfate Treats<\/h2>\n
1. Peptic ulcer disease — gastric and duodenal<\/h3>\n
2. Bile reflux gastritis<\/h3>\n
3. NSAID-associated gastritis and ulcer prophylaxis<\/h3>\n
4. Radiation oesophagitis and proctitis<\/h3>\n
5. Chemotherapy-induced oral mucositis (off-label)<\/h3>\n
6. Stress-ulcer prophylaxis (selected ICU populations)<\/h3>\n
7. Refractory GERD — adjunct to PPI<\/h3>\n
Adagol\u00e1s<\/h2>\n